Merck, Moderna serve 99% of trial patients with mRNA vaccine as personalized shots near market
Personalized cancer vaccines are getting closer to market after Merck and Moderna showed that their mRNA shot–Keytruda combo for melanoma…
Category: Merck
ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer
In a late-stage trial, Merck’s Kelun-Biotech–partnered TROP2 antibody-drug conjugate sacituzumab tirumotecan, better known as sac- TMT, slashed the risk of…
ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak
Data for Merck and Moderna’s highly anticipated personalized cancer vaccine leaked online Thursday morning, days ahead of a headlining reveal…
Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
Antibody-drug conjugates, a groundbreaking cancer vaccine under development by Merck and Moderna and a closely watched PD-1xVEGF bispecific therapy from…